Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes

被引:26
|
作者
Lambadiari, Vaia [1 ,2 ]
Thymis, John [3 ]
Kouretas, Dimitris [4 ]
Skaperda, Zoi [4 ]
Tekos, Fotios [4 ]
Kousathana, Foteini [1 ,2 ]
Kountouri, Aikaterini [1 ,2 ]
Balampanis, Konstantinos [1 ,2 ]
Parissis, John [3 ]
Andreadou, Ioanna [5 ]
Tsoumani, Maria [5 ]
Chania, Christina [5 ]
Katogiannis, Konstantinos [3 ]
Dimitriadis, George [1 ,2 ]
Bamias, Aristotelis [1 ,2 ]
Ikonomidis, Ignatios [3 ]
机构
[1] Natl & Kapodistrian Univ Athens, Med Sch, Attikon Hosp, Dept Internal Med 2,Res Unit, Athens 12462, Greece
[2] Natl & Kapodistrian Univ Athens, Med Sch, Attikon Hosp, Diabet Ctr, Athens 12462, Greece
[3] Natl & Kapodistrian Univ Athens, Med Sch, Attikon Hosp, Dept Cardiol 2, Athens 12462, Greece
[4] Univ Thessaly, Dept Biochem & Biotechnol, Larisa 41500, Greece
[5] Natl & Kapodistrian Univ Athens, Fac Pharm, Lab Pharmacol, Athens 15771, Greece
关键词
glucagon-like peptide-1 receptor agonists; sodium-glucose cotransporter-2 inhibitors; Malondialdehyde; Thiobarbituric Acid Reactive Substances; 2,2(SIC)-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical; BASAL INSULIN GLARGINE; OXIDATIVE STRESS; LIPID-PEROXIDATION; CARDIOVASCULAR EVENTS; HEART-FAILURE; INFLAMMATION; SENESCENCE; REDUCTION; MECHANISM; PROTEINS;
D O I
10.3390/antiox10091379
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (n = 40), liraglutide (n = 40), empagliflozin (n = 40), or their combination (GLP-1RA+SGLT-2i) (n = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2(SIC)-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (p < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (p < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (-8.76% and -9.83%) compared with insulin or SGLT2i (-0.5% and 3.22%), (p < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (-30.15% and -31.44%) compared with insulin or SGLT2i (4.72% and -3.74%), (p < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and -3.44%), (p < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (p < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes
    Ikonomidis, Ignatios
    Pavlidis, George
    Pliouta, Loukia
    Katogiannis, Konstantinos
    Maratou, Eirini
    Thymis, John
    Michalopoulou, Eleni
    Prentza, Vasiliki
    Katsanaki, Eleni
    Vlachomitros, Dimitrios
    Kountouri, Aikaterini
    Korakas, Emmanouil
    Andreadou, Ioanna
    Kouretas, Dimitrios
    Parissis, John
    Lambadiari, Vaia
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (05):
  • [2] Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment
    Ikonomidis, Ignatios
    Pavlidis, George
    Thymis, John
    Birba, Dionysia
    Kalogeris, Aimilianos
    Kousathana, Foteini
    Kountouri, Aikaterini
    Balampanis, Konstantinos
    Parissis, John
    Andreadou, Ioanna
    Katogiannis, Konstantinos
    Dimitriadis, George
    Bamias, Aristotelis
    Iliodromitis, Efstathios
    Lambadiari, Vaia
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (09):
  • [3] Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Zheng, Katina
    Azhie, Amirhossein
    You, Xiaoting
    Naghibzadeh, Maryam
    Tan, Eunice
    Naimimohasses, Sara
    Sridhar, Vikas S.
    Gupta, Sarang
    Chen, Shiyi
    Dash, Satya
    Tsien, Cynthia
    Selzner, Nazia
    Lilly, Leslie
    Jaeckel, Elmar
    Woo, Minna
    Singh, Sunita
    Cherney, David
    Bhat, Mamatha
    DIABETES OBESITY & METABOLISM, 2024, 26 (10) : 4261 - 4272
  • [4] Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany
    Auzanneau, Marie
    Seufert, Jochen
    Zimny, Stefan
    Haak, Thomas
    Zeyfang, Andrej
    Goelz, Stefan
    Hugenberg, Inge
    Pavel, Marianne
    Rosenbauer, Joachim
    Holl, Reinhard W.
    DIABETES OBESITY & METABOLISM, 2024, 26 (09) : 4116 - 4120
  • [5] Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD
    Gregg, L. Parker
    Richardson, Peter A.
    Nambi, Vijay
    Petersen, Laura A.
    Matheny, Michael E.
    Virani, Salim S.
    Navaneethan, Sankar D.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36 (01): : 87 - 98
  • [6] The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
    Dong, Meiyuan
    Wen, Song
    Zhou, Ligang
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2022, 15 : 2583 - 2597
  • [7] Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
    Papazafiropoulou, Athanasia K.
    Melidonis, Andreas
    Antonopoulos, Stavros
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (08) : 1035 - 1042
  • [8] The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes
    Dey, Amit K.
    Groenendyk, Jacob
    Mehta, Nehal N.
    Gourgari, Evgenia
    CLINICAL CARDIOLOGY, 2019, 42 (03) : 406 - 412
  • [9] The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
    Kim, Gwang Sil
    Park, Joong Hyun
    Won, Jong Chul
    ENDOCRINOLOGY AND METABOLISM, 2019, 34 (02) : 106 - 116
  • [10] Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study
    Dong, Yaa-Hui
    Chang, Chia-Hsuin
    Lin, Jou-Wei
    Yang, Wei-Shun
    Wu, Li-Chiu
    Toh, Sengwee
    DIABETES OBESITY & METABOLISM, 2022, 24 (08) : 1623 - 1637